There has been interest in the oral administration of antibodies for localised treatment of infections or other conditions in the gastrointestinal (GI) tract. Download our poster on the interest in the oral administration of antibodies for local treatment of conditions in the gastrointestinal (GI) tract.

Read our scientific poster today titled, 'Working with Short Shelf-Life Products in Clinical Development.'.

Download a copy of our poster from APS 2014 entitled, 'A rapid in vitro screen method for assessing the potential for precipitation of solubilized drugs in the small intestine.'

Development of novel radiolabelling method for low dose drug products for investigation of in Vivo performance in gamma scintigraphic studies. Download our resource first presented at APS 2013 entitled, 'Development of Novel Radiolabelling Method.' 

Formulation selection and development for ME-401, an oral, potent, and selective inhibitor of phosphatidylinositol 3-kinase P110δ during a first-in-human study in healthy volunteers.

Read our scientific poster today titled, 'Formulation Selection and Development for ME-401 Suring a First-in-human Study in Healthy Volunteers.'

This poster describes how combining an intravenous (IV) microtracer regimen with an oral tracer regimen, can generate key pharmacokinetic (PK) parameters. 

Download a copy of our poster from AAPS 2016 titled, '14C Microtracer approaches to inform Formulation development strategies in Early Clinical Drug Development'.

The objective of this poster is to provide comparative information on the CTA and IND applications, highlighting factors that may influence companies in deciding where to conduct Phase I clinical research.

Download our AAPS 2016 scientific poster entitled, "Comparisons between US and UK regulatory environments for conducting Phase I clinical research".

This poster describes a 2 part study combining an IV microtracer study with a conventional oral ADME study.

Read our ISSX scientific poster today titled, 'Using 14C Radiolabeled Clinical Studies to Explore and Evaluate Factors Influencing Oral Exposure.'

This poster explains the cocktail approach for assessing CYP450 drug-drug interaction liabilities including assessment of differential inhibition of liver and gut CYP3A4.

Download our scientific poster from ISSX entitled, 'Cocktail approach for assessing CYP450 drug-drug interaction liabilities'.

Pediatric formulation development is currently a significant topic within the pharmaceutical industry, this poster describes a feasibility study to assess the acceptability of solid dosage forms in children.

Download a copy of our poster presented at EuPFI 2017 entitled. 'A feasibility study to assess the acceptability of solid dosage forms in children'.